Connect Has A Best-In-Class Anti-IL-13 In Eczema, But Won’t Be Taking On Apogee Yet Citeline News & Insights Source link
Expectations For Sanofi’s Dupixent Successor Drop On Latest Eczema Data Citeline News & Insights Source link
Johnson & Johnson Stock (JNJ) Update: Shares Hold Near $208 as Markets Close for the Weekend; Eczema Trial Halt, Pipeline Wins, and 2026 Outlook in Focus ts2.tech Source link